Participants 102 221 6
patients with left ventricular systolic dysfunction and heart failure receiving either candesartan or enalapril or both
Participants 577 706 4
patients with systolic dysfunction and heart failure receiving therapeutic inhibition of the renin-angiotensin-aldosterone system
Participants 888 927 5
768 treated patients with heart failure
